Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,280.00
+220.00 (3.63%)
Last updated: Jun 9, 2026, 2:18 PM KST

Kwang Dong Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
21,62220,96840,48136,96624,17424,019
Depreciation & Amortization
19,54018,05514,53212,90414,01714,110
Loss (Gain) From Sale of Assets
-660.78-7,677-3,0261,964-166.52-38.87
Asset Writedown & Restructuring Costs
2,5902,590----
Loss (Gain) From Sale of Investments
-6,229-7,050-25,399-9,4121,93210,232
Loss (Gain) on Equity Investments
7,08211,441-767.76429.82435.51112.22
Stock-Based Compensation
450.41238.29---17.59
Provision & Write-off of Bad Debts
925.230.582,421517.29478.81-497.04
Other Operating Activities
11,59713,82810,17414,10315,73110,883
Change in Accounts Receivable
6,0841,966-12,401-22,48215,134-14,988
Change in Inventory
-14,78615,419-33,422-33,194-16,56815,153
Change in Accounts Payable
38,10521,772-1,309-7,21320,501-2,987
Change in Unearned Revenue
-278.28-97.619.34-40.20.458.4
Change in Other Net Operating Assets
-33,746-9,011-4,141-6,273-12,848-1,134
Operating Cash Flow
52,22782,341-12,153-11,73062,82254,940
Operating Cash Flow Growth
85.68%---14.35%140.66%
Capital Expenditures
-21,719-29,862-75,730-34,785-25,383-23,795
Sale of Property, Plant & Equipment
717.09992.735,4834,050306.46263.45
Cash Acquisitions
-13,597-13,597----
Divestitures
588.37-----
Sale (Purchase) of Intangibles
-1,173-1,085-1,937-331.65-616.83-651.85
Investment in Securities
-114,185-74,37086,121-14,583-17,896-18,993
Other Investing Activities
3,04311,472-2,395-26,295200.59443.5
Investing Cash Flow
-141,824-102,57812,772-71,831-42,747-42,976
Short-Term Debt Issued
-105,400568,500264,000119,000116,000
Long-Term Debt Issued
--49,88810,000-22,000
Total Debt Issued
135,534105,400618,388274,000119,000138,000
Short-Term Debt Repaid
--108,934-549,605-205,000-99,000-106,000
Long-Term Debt Repaid
--8,303-25,093-1,657-16,510-11,913
Total Debt Repaid
-148,323-117,237-574,698-206,657-115,510-117,913
Net Debt Issued (Repaid)
-12,788-11,83743,69067,3433,49020,087
Issuance of Common Stock
61,65261,652----
Repurchase of Common Stock
--364.46-4,067-6,235--
Dividends Paid
-3,928-3,928-4,008-4,108-4,108-4,108
Other Financing Activities
-229.9-6.471,1501,010-10.5-85.54
Financing Cash Flow
44,70645,51736,76558,010-628.2615,894
Foreign Exchange Rate Adjustments
-329.43-477.371,461-657139.361,226
Miscellaneous Cash Flow Adjustments
--000-00
Net Cash Flow
-45,22024,80238,845-26,20819,58729,084
Free Cash Flow
30,50852,479-87,883-46,51537,43931,145
Free Cash Flow Growth
----20.21%77.30%
Free Cash Flow Margin
1.80%3.16%-5.36%-3.07%2.61%2.33%
Free Cash Flow Per Share
711.461304.16-2194.85-1149.35911.36757.27
Cash Interest Paid
10,43010,56911,6517,5063,7482,369
Cash Income Tax Paid
12,9818,78113,59810,36613,69211,370
Levered Free Cash Flow
72,040101,739-139,015-58,70135,40759,535
Unlevered Free Cash Flow
79,015108,617-132,594-54,38637,74161,125
Change in Working Capital
-4,62230,049-51,254-69,2016,220-3,898